Search Bar & Filters
Found 14 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness of Vagus Nerve Stimulation VNS Therapy as an additional treatment for people with treatment-resistant depression. The study compares active VNS treatment with a no stimulation control over a 12-month period to see if VNS can reduce depressive symptoms measured by several depression scales. This is a prospective, multi-center, randomized, controlled, and blinded trial involving subjects who have VNS devices implanted. Participants receive the VNS implant, and after at least two weeks, they are randomized to either have the device activated or not activated for the first 12 months. Those in the control group can receive stimulation after 12 months. After the initial 12-month randomized phase, all participants transition into an open-label, long-term study lasting about 5 years. New subjects may also enroll directly into this extension phase. During the trial, participants are assessed regularly using multiple depression rating scales and questionnaires to monitor changes in symptoms, response times, remission, and adverse events. Safety and quality of life measures are also tracked. The study includes thorough monitoring of depressive symptoms and overall functioning for up to 12 months post-randomization, followed by long-term observation for several years.
Actively Recruiting
Researchers are evaluating the efficacy and safety of eloralintide compared with placebo in adults with persistent obesity or overweight. Participants may have type 2 diabetes or not, and all are on stable background therapy with a weekly incretin. This phase 3 randomized, double-blind study aims to understand the effects of eloralintide on body weight and related health outcomes. Participants will be randomly assigned to receive one of four doses of eloralintide or a placebo, all given by subcutaneous injection once weekly. The study treatment period lasts for 64 weeks, during which participants receive their assigned injections. This is a parallel group study, meaning each participant receives only one assigned treatment throughout the trial. Participant involvement spans about 80 weeks, including screening, treatment, and follow-up. Researchers will monitor changes in body weight, waist circumference, blood pressure, blood sugar, insulin, kidney function, inflammation markers, and quality of life using questionnaires. Safety and medication use will also be tracked. Visits and assessments will occur regularly to evaluate the treatment effects and participant well-being.
Actively Recruiting
Bipolar disorder is a serious and chronic mood condition affecting both adults and pediatric populations in the United States. This research aims to evaluate the safety and effectiveness of Icalcaprant in treating adults diagnosed with bipolar I or II disorder, focusing on depressive episodes. The study is a phase 2, randomized, placebo-controlled trial enrolling about 195 adults across approximately 35 sites. Participants will be randomly assigned to one of three groups two different doses of oral Icalcaprant or a matching placebo. They will take the assigned oral capsules once daily for six weeks. After the treatment period, there will be a four-week safety follow-up to monitor participants health. During the study, participants will attend regular visits at hospitals or clinics for medical assessments, blood tests, side effect monitoring, and questionnaires. The main outcomes measured include changes in depression severity using the Montgomery-sberg Depression Rating Scale and monitoring adverse events throughout the treatment and follow-up periods. This study is sponsored by AbbVie and aims to better understand treatment options for bipolar depression.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of camlipixant in adults diagnosed with irritable bowel syndrome with diarrhea IBS-D and mixed irritable bowel syndrome IBS-M. This phase 2b study is designed to compare camlipixant with a placebo in relieving abdominal symptoms. The study includes two parts, with some participants randomly assigned in the second part to receive either a higher dose of the drug or to stop treatment. Participants will receive different doses of camlipixant or placebo during the first part of the study. In the second part, participants may receive either placebo or camlipixant again, allowing researchers to assess the effects of dose adjustments. The dosing levels include three different doses of camlipixant compared with placebo. The study treatment is given under double-blind conditions, meaning neither participants nor researchers know who receives which treatment. Throughout the study, participants will be monitored for changes in abdominal pain intensity and stool consistency over 12 weeks, with safety assessments continuing up to 26 weeks. Researchers will collect data on abdominal pain scores, stool form, global improvement, and any side effects or adverse events. Regular evaluations include physical exams, laboratory tests, and heart monitoring. Participants are expected to be involved in scheduled visits and assessments to track the study outcomes and ensure safety.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of subcutaneous treatment with lunsekimig compared with placebo in adults aged 40 to 80 years who have inadequately controlled Chronic Obstructive Pulmonary Disease COPD characterized by an eosinophilic phenotype. This Phase 2bPhase 3 study includes participants with a history of COPD, ongoing symptoms despite treatment, and specific lung function and blood eosinophil criteria. Participants will be randomly assigned to one of three groups lunsekimig dose regimen A, lunsekimig dose regimen B, or a placebo group. All treatments are given as subcutaneous injections during a 48-week treatment period. The study consists of a screening period up to 4 weeks, followed by the 48-week randomized treatment, and then an approximately 8-week follow-up period, totaling up to 60 weeks of participation. During the study, participants will undergo lung function tests, symptom and quality of life questionnaires, and blood tests to monitor eosinophil counts and drug levels. The main outcome measured is the annualized rate of moderate-to-severe COPD exacerbations over 48 weeks. Additional assessments include changes in lung function, symptom scores, safety events, and antibody development. Safety monitoring continues through the follow-up period after treatment ends.
Actively Recruiting
This research aims to evaluate the investigational Nevisense Go device for collecting skin measurements from people with atopic dermatitis AD, a condition marked by flare-ups of worsening skin symptoms. The study focuses on participants aged 12 to 89 years who have experienced recent AD flares. It is based on the idea that changes in skin barrier function may happen before visible signs or symptoms of a flare appear. Participants will use the Nevisense Go device at home for about 90 days to measure electrical properties of their skin related to skin barrier function. The study is observational, meaning device measurements will not guide treatment or care. Alongside device use, participants will complete electronic symptom diaries and attend up to five in-person study visits during the study period. During the study, researchers will assess the relationship between skin measurements and AD flares, develop and validate an algorithm using the device data, and evaluate AD severity through patient-reported and clinician-reported outcomes. They will also assess flare resolution, device feasibility, and participant adherence. The total participation lasts approximately 90 days with repeated measurements and study visits throughout this time.
Actively Recruiting
Researchers are evaluating ORKA-002, a drug administered by subcutaneous injection, in adult participants with moderate-to-severe Hidradenitis Suppurativa HS. This multicenter, randomized, double-blind, placebo-controlled study aims to assess the efficacy, safety, tolerability, and pharmacokinetics of ORKA-002 compared to placebo. The study is sponsored by Oruka Therapeutics, Inc. and involves participants who have had HS symptoms for at least 6 months with lesions in multiple areas and prior inadequate response or intolerance to systemic antibiotics. Participants will be randomly assigned to receive either ORKA-002 or placebo every 4 weeks during a 12-week double-blind induction period through Week 16. After this, all participants will enter an open-label maintenance period where ORKA-002 is given every 12 weeks. The study includes four distinct periods screening, induction double-blind, maintenance open-label, and post-treatment follow-up. During the study, participants will undergo regular assessments including the Hidradenitis Suppurativa Clinical Response HiSCR75 at Week 16, symptom diaries tracking worst skin pain, and safety monitoring through vital signs, laboratory tests, and electrocardiograms. The total study participation may extend through Week 92 for ongoing safety evaluations. Participants will also be monitored for adverse events throughout the study duration.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of icovamenib in adults with Type 2 Diabetes T2D who are not meeting blood sugar targets despite using GLP-1-based therapy. This phase 2 randomized, double-blind, placebo-controlled trial focuses on participants who have been treated with GLP-1 for at least three months but still have elevated HbA1c levels above the target set by the American Diabetes Association. Participants will be randomly assigned to receive either icovamenib 100 mg once daily or a matching placebo, alongside their current GLP-1 or GIPGLP-1 receptor agonist regimen. This treatment phase lasts for 12 weeks. Afterward, all participants continue on a stable dose of their baseline GLP-1-based therapy, such as Ozempic, for the remainder of the study. The total trial duration is about 57 weeks, including screening and follow-up. Throughout the study, participants will undergo regular evaluations including blood tests to measure HbA1c and monitor glycemic control. Researchers will track adherence to medication and assess safety and treatment effects during the 12-week treatment period and follow-up. The main goal is to determine if icovamenib improves blood sugar control better than placebo over 26 weeks, with the entire participation lasting nearly a year.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a topical medication called roflumilast foam 0.3% in adolescents and adults with Hidradenitis Suppurativa HS, a chronic inflammatory skin condition causing painful lumps and abscesses in areas like the underarms, groin, and buttocks. This phase 2 study focuses on patients with mild to moderate HS Hurley Stage I or II and aims to assess treatment outcomes over 16 weeks. Participants will apply the investigational roflumilast 0.3% topical foam once daily to all active HS lesions for the duration of 16 weeks. The study is open-label with a single group receiving the same treatment. No placebo or comparator group is involved. Patients must avoid certain antibiotics, steroids, and topical antiseptics during the study, and females of childbearing potential must use effective contraception. Throughout the trial, participants will be monitored for changes in the number of abscesses and inflammatory nodules from baseline to week 16. Safety and adherence will be assessed through clinical evaluations, including physical exams and pregnancy tests when applicable. The total study duration per participant is 16 weeks, with scheduled visits to track progress and response to the topical treatment.
Actively Recruiting
Researchers are studying two experimental drugs, REGN7508 and REGN9933, in people with atrial fibrillation, a condition where the heart beats irregularly and too fast. The study aims to see how these drugs work to prevent blood clots compared to apixaban, a currently available medicine. The research also looks at potential side effects, how well the drugs reduce stroke risk, drug levels in the blood, and whether the body develops antibodies that might affect the drugs action or safety. Participants will be randomly assigned to receive either REGN7508, REGN9933, or apixaban. All treatments are given according to the study protocol. The study lasts about 12 weeks for the main bleeding safety measurements, with some evaluations continuing up to about 25 weeks to monitor adverse events, antibody development, and blood drug concentrations. Throughout the study, participants will have regular assessments to check for bleeding events, strokes, and treatment side effects. Blood tests will measure drug levels and blood clotting times. Researchers will track safety and effectiveness by comparing bleeding incidents and other outcomes between the different treatments. The total participation time covers the treatment period and follow-up visits up to about 25 weeks.
1-10 of 14
1